By Randi Hernandez Peptides and proteins generally have low bioavailability when taken by mouth, and this hurdle has generally prevented the oral delivery of many biologic drugs in the past. However, plant cell walls may be ideal transporters to move protein-based drugs through the digestive system without the drugs being exposed to degradation by stomach[…]
More than one-third of U.S. patients with the abnormal heartbeat atrial fibrillation who need a blood thinner to prevent strokes aren’t getting one, researchers say. About 40 percent of “a-fib” patients deemed at moderate to severe risk of stroke because of age or other conditions are prescribed aspirin alone rather than recommended blood thinners such[…]
In July 2015, the FDA approved alirocumab (Praluent), the first cholesterol-lowering treatment in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. The following month, the FDA approved the second PCSK9 inhibitor, evolocumab (Repatha). http://www.slideshare.net/VinceNetto/pcsk9-inhibitors-pp This article highlights several key therapeutics areas for Praluent and Repatha that every[…]